NEWS AND NOTES Mid-summer 2022 A Zoom Meeting due to coronavirus COVID 19

From National Cancer Institute: A multidisciplinary tumor board review of medical records; to	
	find out how to submit your medical records contact Dr. Del Jaydira Del Rivero, MD, Director of the
	Center for Cancer Research Neuroendocrine Tumor Program: jaydira.delrivero@nih.gov
From LACNETS	** Weekly support group meetings each Wednesday, noon PT (3 PM ET)
	**Health & Wellness Virtual Retreat Saturday August 13 th , registration at their website
	**Live Webinar: Update on Lung NETs with Dr. Sukhmani Padda, Thursday August 25 th (12 PM PT)
	registration on their website
From NETRF	**conference July 24 th : KNOW YOUR NETs 2022 Virtual Conference - NETRF
From Pheo Para Alliance: **Patient Conference August 21-25: Pheo Para Patient Conference - Pheo Para Alliance	
From NETRF	**A Patient's Guide to NETs is available through their website
	**A Research Study that looks at connection between NETs and COVID-19 infection outcomes
	**An eNET Study to learn about symptoms and quality of life for NET patients
	**NETWise podcasts
From CCF	**Partnership with Clarified Precision Medicine to offer NET patients the opportunity to receive an
	expert review of their tumor sequencing. Please see: clarifiedprecisionmedicine.com/clarifiedselect
	**Weekly Lunch with the Experts features conversations each Thursday at noon on CCF Facebook Live,
	always available in their Video file, and posted on the CCF YouTube channel the following Monday
	**NET Cancer Health Storylines is available from the CCF website; use it on your desktop or phone
	https://www.healthstorylines.com/net-cancer-
	healthstorylines?fbclid=IwAR1lz8N_68HtYNAz09b64rTp4Mq0UlvMjEUtTBweiYf9Qb1yruHlRyb3vu4
	** Ask the NET Experts – A New CCF Program:
	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788218?fbclid=IwAR0rtLuLbYI75XpQ
	EbVC878rMe-yFDKK9bvHGUap1zmqIhV_3t_BG6SqQMg
From The Healing NET Foundation: **Patient Care booklet <i>Navigating the NET Patient Journey</i> is available online from	
	their website as well as their Neuroendocrine Tumors: A Primer for Healthcare Professionals
	**New Guide on High-Grade NECs: <u>https://www.carcinoid.org/2021/11/09/new-guide-on-high-grade-</u>
	neuroendocrine-cancers/
From LACNETS	**NET Vitals: worksheet to record your medical history: <u>https://www.lacnets.org/lacnets-blog/netvitals</u>
	**What's New with NETS webinar by Dr. Pamela Kunz:
	https://www.youtube.com/watch?v=fdQvnIR3bRQ
From Lisa at TerSera Therapeutics: ** For support with CS, please go to <u>www.enrollxermelo.com</u> and opt in. Once	
	completed, a nurse educator will contact you within 48 hours. For the nursing support program:
	www.thenetnurse.com
	**Find Food You Love:
From Lexicon	**A Nutrition Guide: sign up via link: <u>https://community.aboutcarcinoid.com/</u>
	**Also available from through CCF: <u>https://www.carcinoidsyndrome.org/2017/12/19/nutrition-recipe-</u>
	guide-people-gastrointestinal-neuroendocrine-tumors-carcinoid-
	syndrome/?fbclid=IwAR2fsqItfegz0ZpYEraraT-j9MzZ1d9RzQfId_yX7OrBtMpcJZtAVH5Hfb0
NEW ARTICLES: From Mike and Chuck: Amryt Receives Orphan Drug Designation from the FDA for Mycapssa [®] (oral	
	octreotide) for the Treatment of Carcinoid Syndrome: Amryt Receives Orphan Drug Designation from

the FDA for (globenewswire.com) From Mike and Chuck: Mycapssa: MYCAPSSA® (octreotide) delayed-release oral capsules

From Mike and Chuck: The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases: <u>cancers-14-03415.pdf</u>

From Mike and Chuck: Sequencing of Therapies in Progressive NETs: <u>Sequencing of Therapies in</u> <u>Progressive Neuroendocrine Tumors | SpringerLink</u>

From the July 7, 2022 CCF Luncheon with the Experts Dr. Diane Reidy-Lagunes: <u>Diane Reidy-Lagunes</u> <u>Memorial Sloan Kettering Cancer Center (mskcc.org)</u>

From the July 7, 2022 CCF Luncheon with Dr. Reidy: What is Dostarlimab, the Drug Used in the 'Unprecedented' Cancer Trial? <u>Dostarlimab: What Is the Drug With Unprecedented Cancer Trial</u> <u>Results? – NBC New York</u>

From the CCF Luncheon with Dr. Reidy: Lung NETs and DIPNECH: (1) Lung Neuroendocrine Tumors and DIPNECH - YouTube

From the CCF Luncheon with Dr. Reidy: Cancer Straight Talk Podcast from MSK: <u>Cancer Straight Talk</u> <u>Podcast from MSK | Memorial Sloan Kettering Cancer Center | Memorial Sloan Kettering Cancer Center</u> (<u>mskcc.org</u>)

From the CCF Luncheon with the Experts Dr. Jaydira Del Rivero: <u>Jaydira Del Rivero, M.D. | Center for</u> <u>Cancer Research</u>

From the CCF Luncheon with Dr. Del Rivero: Unique Opportunity for NET patients: <u>email : Webview :</u> <u>Unique Opportunity for Neuroendocrine Tumor Patients (e2ma.net)</u>

From the CCF Luncheon with Dr. Del Rivero: Tissue Procurement and Natural History Study of NENs including Adrenocortical Carcinoma (ACC): <u>Tissue Procurement and Natural History Study of</u>

<u>Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) - Full Text View -</u> <u>ClinicalTrials.gov</u>

From the CCF Luncheon with the Experts Dr. Philip A. Philip: <u>Philip Philip, MD | Henry Ford Health -</u> <u>Detroit, MI</u>

From the CCF Luncheon with the Experts Dr. Nitya Raj: <u>Nitya Raj | Memorial Sloan Kettering Cancer</u> <u>Center (mskcc.org)</u>

From the CCF Luncheon with Dr. Raj: 'Unprecedent' 100% of First 14 Untreated Patients with Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly: <u>'Unprecedented' 100% of First 14 Untreated Patients</u> With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly - The ASCO Post

From the CCF Luncheon with Dr. Raj: Nutrition and Recipe Guide for People with Gastrointestinal NETs and Carcinoid Syndrome: <u>Nutrition and Recipe Guide for People with Gastrointestinal Neuroendocrine</u> <u>Tumors and Carcinoid Syndrome - Carcinoid Syndrome</u>

From Pat, via MSKCC newsletter: Rectal Cancer Disappears After Experimental Use of Immunotherapy: <u>Rectal Cancer Disappears After Experimental Use of Immunotherapy | Memorial Sloan Kettering Cancer</u> <u>Center (mskcc.org)</u>

From Randy: Cancer Trial's Unexpected Result: Remission in Every Patient Small Study on Rectal Cancer Results in Remission in Every Patient - The New York Times (nytimes.com)

RECURRING ARTICLES:

From Mike and Chuck: Drug combination shows promise for treating pNETs:

Drug combination shows promise for treating pNETs | EurekAlert!

From Mike and Chuck: New Therapy Options for NECs of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo: <u>Cancers | Free Full-Text | New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo (mdpi.com)</u>

From Mike and Chuck: Good Response With ONC201 for Rare NETs: <u>https://journals.lww.com/oncology-times/Fulltext/2022/05050/Good_Response_With_ONC201_for_Rare_Neuroendocrine.5.aspx?context=FeaturedArticles&collectionId=2</u>

From Mike and Chuck: In patients with well-differentiated NETs, there is no apparent benefit of SSAs after disease control by PRRT: <u>https://pubmed.ncbi.nlm.nih.gov/35503379/</u>

From Chuck, from MedPage: HUTCHMED Receives Complete Response Letter from the US FDA for Surufatinib for the Treatment of Advanced NETs: <u>https://www.hutch-med.com/wp-</u> content/uploads/2022/05/a220502 HKEX E.pdf

From Chuck: Updated Guidance for COVID-19 Vaccination from NCCN Recommends Fifth mRNA Shot (Second Booster Dose) for Immunocompromised People:

https://www.nccn.org/home/news/newsdetails?NewsId=3252

From Pat, from NANETS: Survival and Incidence Patterns of Pancreatic NETs over the Last 2 Decades: A SEER Database Analysis: <u>https://academic.oup.com/oncolo/advance-</u>

article/doi/10.1093/oncolo/oyac049/6555099?login=false

Link for Sunnybrook Health Sciences Centre:

https://sunnybrook.ca/content/?page=neuroendocrine-tumour-

cancer&fbclid=IwAR1CGJGYUwqZqzSmqnFNoJ-s1uMwux9PYqc6be2i7T9fDUN-taYlZqfOLGU

Link for CNETS, Canadian Neuroendocrine Tumour Society:

https://cnets.ca/?fbclid=IwAR1wPLO6_QLCq7goUD_Xia4v5eP77mBP-pTbMBo_GfV1UNry5rMInBEzTVI From Mike and Chuck: Prognostic significance of laterality in lung NETS:

https://pubmed.ncbi.nlm.nih.gov/35301675/

From Mike and Chuck: INCA Global NET Patient Information Pack:

https://incalliance.org/net-info-packs/

From Chuck: Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline Autogel/Somatuline Depot (Lanreotide) designed to improve patient experience:

https://www.ipsen.com/press-releases/ipsen-announces-investment-in-new-state-of-the-art-electronicautoinjector-for-somatuline-autogel-somatuline-depot-lanreotide-designed-to-improve-patientexperience/

From Mike, referenced during our March and April zoom meetings: Gebauer's Pain Ease: <u>https://www.gebauer.com/pain-ease-procedural-video-wf</u>

From Mike and Chuck: Circulating Progastrin, a Novel Blood-Based Biomarker for Detection of Poorly Differentiated NEC and Well Differentiated NETs: <u>https://www.mdpi.com/2072-</u>

6694/14/4/863/review_report

From Mike: Diagnostic value of Ga68 Ga-DOTA-labeled-somatostatin analogue PET/MRI for detecting liver metastasis in patients with NETs: a systematic review and meta-analysis:

https://link.springer.com/article/10.1007/s00330-021-08527-z

From Pat: Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix [™] for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers:

https://www.globenewswire.com/news-release/2022/01/03/2360157/0/en/Radiomedix-and-Orano-Med-Announce-the-Initiation-of-the-Phase-II-Multi-Center-Clinical-Trial-of-Alphamedix-for-Targeted-Alpha-Emitter-Therapy-of-Neuroendocrine-Cancers.html

From CCF: Management of Large Cell Neuroendocrine Carcinoma:

https://www.frontiersin.org/articles/10.3389/fonc.2021.653162/full?fbclid=IwAR3ZAFccVMeoSHWjPiHe X5m-KJombhcU1atIfrxL2piSICVd9rsL7_d8U54

From Jacq: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic NET (pNET) (MK-6482-015): <u>https://clinicaltrials.gov/ct2/show/NCT04924075</u> From Mike and Chuck: Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts NET Recurrence with 94% Accuracy:

https://pubmed.ncbi.nlm.nih.gov/34183517/

From Mike and Chuck: Tidutamab Induces Best Overall Response of Stable Disease in Advanced NETs: <u>https://www.oncnursingnews.com/view/tidutamab-induces-best-overall-response-of-stable-disease-in-advanced-neuroendocrine-tumors</u>

From Mike and Chuck: Lanreotide Demonstrates confirmed Efficacy in Advanced Bronchopulmonary NETS: <u>https://www.onclive.com/view/lanreotide-demonstrates-confirmed-efficacy-in-advanced-bronchopulmonary-nets</u>

From Mike and Effie: Liquid Biopsy Blood Biomarker Possible Predictor of Tumor Recurrence, Cost Savings: <u>https://www.ajmc.com/view/liquid-biopsy-blood-biomarker-possible-predictor-of-tumor-recurrence-cost-savings</u>

From Chuck: NETs require individualized treatment approach:

https://www.healio.com/news/hematology-oncology/20211021/neuroendocrine-tumors-requireindividualized-treatment-approach

From Chuck: A Novel Liquid Biopsy (NETest) identifies Paragangliomas and Pheochromocytomas with High Accuracy: <u>https://pubmed.ncbi.nlm.nih.gov/34515661/</u>

From Chuck: A Multigenomic Liquid Biopsy Biomarker for NET Disease outperforms CgA and has Surgical and Clinical Utility: <u>https://www.semanticscholar.org/paper/A-Multigenomic-Liquid-Biopsy-Biomarker-for-Tumor-Modlin-</u>

<u>Kidd/4b9b1458b64083a8cf83336ed0c6e500708186e9?utm_source=alert_email&utm_content=AuthorP</u> aper&utm_campaign=AlertEmails_WEEKLY&utm_term=AuthorPaper&email_index=0-0-0&utm_medium=2488505

NCCN (National Comprehensive Cancer Network) Guidelines for Patients:

https://www.nccn.org/patients/guidelines/content/PDF/neuroendocrine-patient.pdf

European Neuroendocrine Tumor Society (ENETS): <u>https://www.enets.org/current_guidelines.html</u> Canadian Neuroendocrine Tumour Society (CNETS): <u>https://cnets.ca/patients-caregivers/resources/438-</u> 2/

Wren Laboratories:

https://www.wrenlaboratories.com/?fbclid=IwAR1O8YIMR7mPSyDi88jUjrVZrR5I3UoAy9JnBvbZ2pVk9q WnQjggednSMXY

FAQs NET Tissue Donation: <u>https://netrf.org/2019/06/12/faqs-tumor-tissue-</u>

<u>donation/?fbclid=lwAR1_q5Pvl_6eKWvwtmaMSBEaDCBw-_wMbPHKnXxTdcfEg0KFpq6Awc-RQa4</u> Your Surgery or Fluid Drain can Advance Cancer Research:

https://pattern.org/?fbclid=IwAR16DOxL6VScbv5Ql5DTG99T3SpRiZuU0gCbID5WiyEXxA4PYEbhbgZU9nl From Chuck: 'I'm a Cardiologist, and Here's What It Really Means When You're Out of Breath From Walking Up the Stairs' <u>https://www.msn.com/en-us/health/fitness/i-m-a-cardiologist-and-here-s-whatit-really-means-when-you-re-out-of-breath-from-walking-up-the-stairs/ar-BB1f5ZJC?ocid=msedgdhp</u>

Please see our website (njcarcinoidnetwork.org) for additional articles

Other items of interest:

- From Randy at the February 6th Zoom meeting: **List of Apps for compiling your medical records: <u>https://tinyurl.com/2pd5y9w3</u>
- From a Facebook group: **Ga68 and PRRT are available at Hackensack Medical Center: Dr. Martin Gutierrez, oncologist, Dr. Brett Lewis, radiologist
- From Marilyn: **PRRT with Lutathera is available to St Barnabas in Livingston; the head of department is Dr Scoppetuolo who was Ralph's doctor
- From a patient on ACOR: **Eovist contrast has "more distribution and excretion pathways...which allows for an additional contrast phase in the scan and more information to aid in diagnosis." Ask for it specifically, even with the technician or radiologist who is performing the scan.
- Patient Access Network: **from Jim and Janet: Member services 1-800-806-7501, Benefits information: 1-800-316-7263. "Medical information has to be completed by the provider's office; PAN has been able to assist in handling out of pocket expenses, deductible for specific chemo drugs; all other insurances are used first."
- Patient resources suggested by Lynn in Monmouth County: **the Livestrong Program at the Red Bank YMCA; the

Monmouth Medical Center Cancer Support Group; and **Mary's Place by the Sea in Ocean Grove - a respite home for women receiving treatment for cancer <u>https://www.marysplacebythesea.org</u>

Amazon Smile Foundation: we receive **\$.005** for every dollar spent on eligible purchases. Go to: smile.amazon.com ISI InterScience Institute: to request a copy of their biomarker testing code book go to interscienceinstitute.com, or

download a PDF version

Organizations and websites:	
Carcinoid Cancer Foundation: CCF	
Neuroendocrine Carcinoid Awareness: NCAN	
Neuroendocrine Tumor Research Foundation: NETRF	
The Healing NET Foundation	
Clinical Trials information	
Ronny Allan blog	
Carcinoid Syndrome from CCF	
NET Patient Foundation	
LACNETS: Los Angeles Carcinoid NET Society	

Discussion boards:

Facebook groups:

Find them at

carcinoid.org netcancerawareness.org netrf.org; newsletter available thehealingnet.org; newsletter available clinicaltrials.gov ronnyallan.com carcionoidsyndrome.org netpatientfoundation.org (located in London) lacnets.org

ACOR.org (find the carcinoid group) Smartpatients.com (find the carcinoid group) Inspire.com (Lung NET group, others)

Carcinoid Coffee Café Lovable Lungnoids Dr Liu's Zebras: A Neuroendocrine Cancer Community **NET Patients Sharing Knowledge & Experience** Carcinoid Neuroendocrine Cancer Awareness Carcinoid Connection (also: carcinoid.com) Carcinoid Awareness (also: aboutcarcinoid.com) Zebra Caregivers Talk NETS (no patients) My Dazzle (sponsored by Lexicon) **NETs get COOKING** Green Zebras (cannabis for NET cancer) Young Zebras: A Support Group for Young NET Cancer patients and their caregivers **ZEBRA** awareness Global NETS Zebra Zone: NET cancer Support Group (linked to Neuroendocrine Cancer Connection)